Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines

Kelonia Therapeutics focused on vivo gene delivery, launched with a $50M in funding to expand the benefit and reach of genetic medicines.

What You Should Know:

– Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding to expand the benefit and reach of genetic medicines.

– Despite life-changing responses, existing gene therapies are highly complex, costly, and limited by complicated treatment paradigms, tractable therapeutic applications, and dose-limiting toxicities. By enabling precisely targeted, highly efficient, manufacturable “off-the-shelf” in vivo gene delivery, Kelonia’s technology has the potential to dramatically expand the impact and reach of genetic medicines to every patient in need.